Published in Cancer Weekly, October 24th, 2000
This disease is the second leading cause of cancer death, with an estimated 56,300 men and women expected to die this year in the United States alone. The study showed patients receiving the new regimen had improved tumor response rates and improved overall survival as compared to those on standard treatment.
The combination therapy, developed by Dr....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.